



Publication of a transparency notification received from The Goldman Sachs Group Inc.

Liege, Belgium, 22 December 2023 – 17:45 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces, in accordance with Article 14 of the Belgian Law of 02, May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received on the 20 December 2023 a notification of transparency from The Goldman Sachs Group, Inc with registered offices at 1209 Orange Street, Wilmington, DE 19801, USA.

The Goldman Sachs Group, Inc. notified Mithra that it has dropped below the statutory notification-threshold of 3% of the 69,108,397 shares currently outstanding on 13 December 2023 to 2.99% (2 065 335 shares) of shares outstanding. Previously, The Goldman Sachs Group, Inc. held 3.41% (2 359 668 shares) of Mithra's outstanding securities.

The detailed transparency notifications are available on the [Investors section of Mithra website](#). An updated overview of Mithra's shareholders structure will be included in the corporate governance charter of Mithra, which will be made available on its website.

For more information, please contact:

Mithra Pharmaceuticals SA

Alex Sokolowski, PhD
Head of IR & Communications
investorrelations@mithra.com
+32 (0)4 349 28 22

Frédérique Depraetere
Communications Director
info@mithra.com
+32 (0)4 349 28 22

About Mithra

Mithra Pharmaceuticals SA (Euronext: MITRA) is a Belgian biopharmaceutical company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill ESTELLE®, Mithra is now focusing on its second product DONESTA®, the next-generation hormone therapy. Mithra also offers partners a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes or cartridges) at its technological platform Mithra CDMO. Active in more than 100 countries around the world, is headquartered in Liège, Belgium. www.mithra.com

ESTELLE® and DONESTA® are registered trademarks of Mithra Pharmaceuticals or one of its affiliates.

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

A circular logo with a teal background and white text that reads "News Alerts".

Subscribe to our mailing list on investors.mithra.com to receive press releases by email or follow us on social media:

[Linkedin](#) • [X](#) • [Facebook](#)